Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins⏵

Other
Feedback
Home
Top
All convalescent plasma..
 
Feedback
Home
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta
Home Adoption Other Treatments

Outcomes in COVID-19 convalescent plasma studies

Home
Tweet
Share
@CovidAnalysis
StudiesStudies
Adoption
FeedbackFeedback
All studies   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -1% 42 24,249 Improvement, Studies, Patients Relative Risk Mortality -0% 41 23,179 Ventilation 2% 14 2,626 ICU admission -15% 6 2,275 Hospitalization 4% 12 3,290 Progression 2% 12 2,659 Recovery -0% 8 13,798 Viral clearance 17% 6 1,021 RCTs -0% 39 23,813 RCT mortality 0% 38 22,743 Peer-reviewed -0% 38 23,876 Early -36% 5 1,508 Late -0% 37 22,741 Convalescent Plasma for COVID-19 c19early.org Sep 2023 Favorsconv. plasma Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 36% higher risk Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Improvement, RR [CI] Treatment Control Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Gonzalez -7% 1.07 [0.76-1.50] death 60/130 26/60 OT​1​ Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] death 3/30 5/30 Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] death 16/59 5/15 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] death 18/80 13/80 COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] death 10/69 8/67 CAPRI Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] death 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] death 11/53 17/52 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] death 14/231 19/240 Holm (RCT) 45% 0.55 [0.11-2.84] death 2/17 3/14 CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] death 40 (n) 39 (n) Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Jalili (RCT) -45% 1.45 [0.74-2.87] death 16/60 11/60 Baldeón (DB RCT) 12% 0.88 [0.37-2.11] death 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] death 11/52 13/51 De Santis (RCT) 13% 0.87 [0.48-1.56] death 11/36 25/71 Rojas (SB RCT) -220% 3.20 [0.64-16.0] death 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] death 22/87 7/42 CORIPLASM Lacombe (RCT) 49% 0.51 [0.20-1.32] death 7/60 12/60 CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] death 15/98 4/46 PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] death 89/482 80/465 REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] death 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] death 68 (n) 66 (n) CSSC-004 Baksh (DB RCT) -1% 1.01 [0.94-1.09] no recov. 381/538 381/532 Alshamrani (PSM) -14% 1.14 [0.79-1.45] death 24/41 108/205 Krishnan -270% 3.70 [0.90-15.8] death case control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.85 Late treatment -0% 1.00 [0.96-1.05] 2,789/11,763 2,711/10,978 0% higher risk All studies -1% 1.01 [0.96-1.05] 2,802/12,516 2,721/11,733 1% higher risk 42 convalescent plasma COVID-19 studies c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.82 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 36% higher risk Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Improvement, RR [CI] Treatment Control Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Gonzalez -7% 1.07 [0.76-1.50] 60/130 26/60 OT​1​ Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] 3/30 5/30 Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] 16/59 5/15 Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] 18/80 13/80 COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] 10/69 8/67 CAPRI Hsue (DB RCT) -212% 3.12 [0.14-71.7] 1/16 0/18 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] 11/53 17/52 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] 14/231 19/240 Holm (RCT) 45% 0.55 [0.11-2.84] 2/17 3/14 CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] 59/462 71/462 PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] 40 (n) 39 (n) Sullivan (DB RCT) 86% 0.14 [0.01-2.75] 0/592 3/589 Jalili (RCT) -45% 1.45 [0.74-2.87] 16/60 11/60 Baldeón (DB RCT) 12% 0.88 [0.37-2.11] 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] 11/52 13/51 De Santis (RCT) 13% 0.87 [0.48-1.56] 11/36 25/71 Rojas (SB RCT) -220% 3.20 [0.64-16.0] 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] 22/87 7/42 CORIPLASM Lacombe (RCT) 49% 0.51 [0.20-1.32] 7/60 12/60 CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] 15/98 4/46 PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] 89/482 80/465 REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] 68 (n) 66 (n) Alshamrani (PSM) -14% 1.14 [0.79-1.45] 24/41 108/205 Krishnan -270% 3.70 [0.90-15.8] case control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.94 Late treatment -0% 1.00 [0.95-1.05] 2,408/11,225 2,330/10,446 0% higher risk All studies -0% 1.00 [0.96-1.05] 2,421/11,978 2,340/11,201 0% higher risk 41 convalescent plasma COVID-19 mortality results c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.91 ​1​ OT: comparison with other treatment Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -163% 2.63 [0.43-9.10] 5/28 2/30 Gharbharan (DB RCT) 67% 0.33 [0.01-8.16] 0/207 1/209 Tau​2​ = 0.30, I​2​ = 22.8%, p = 1. Early treatment 0% 1.00 [0.28-3.54] 7/315 7/319 0% lower risk PLACID Agarwal (RCT) 1% 0.99 [0.54-1.81] 19/227 19/224 Improvement, RR [CI] Treatment Control Bajpai (RCT) -221% 3.21 [0.38-27.4] 3/14 1/15 AlQahtani (RCT) 33% 0.67 [0.22-2.01] 4/20 6/20 CAPRI Hsue (DB RCT) -425% 5.25 [0.27-102] 2/16 0/18 DAWn-plasma Devos (RCT) -8% 1.08 [0.65-1.80] 320 (n) 163 (n) TSUNAMI Menichetti (RCT) -4% 1.04 [0.62-1.75] 25/231 25/240 Holm (RCT) 69% 0.31 [0.01-7.09] 0/17 1/14 PennCCP2 Bar (RCT) 51% 0.49 [0.18-1.30] 5/40 10/39 PROTECT-Patient van den Berg (RCT) 67% 0.33 [0.04-3.04] 1/52 3/51 CCAP-2 Thorlaci.. (DB RCT) -37% 1.37 [0.29-6.52] 6/94 2/43 Denkinger (RCT) -2% 1.02 [0.59-1.77] 19/68 18/66 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.87 Late treatment 2% 0.98 [0.76-1.25] 84/1,099 85/893 2% lower risk All studies 2% 0.98 [0.77-1.25] 91/1,414 92/1,212 2% lower risk 14 convalescent plasma COVID-19 mechanical ventilation results c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.89 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 67% 0.33 [0.07-1.60] 2/80 6/80 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.17 Early treatment 67% 0.33 [0.07-1.60] 2/80 6/80 67% lower risk DAWn-plasma Devos (RCT) 0% 1.00 [0.74-1.34] 320 (n) 163 (n) Improvement, RR [CI] Treatment Control Sullivan (DB RCT) 25% 0.75 [0.17-3.32] 3/592 4/589 Jalili (RCT) -8% 1.08 [0.72-1.63] 27/60 25/60 CCAP-2 Thorlaci.. (DB RCT) -31% 1.31 [0.45-3.82] 12/89 4/39 Alshamrani (PSM) -43% 1.43 [1.13-1.80] 37 (n) 166 (n) Tau​2​ = 0.00, I​2​ = 4.8%, p = 0.036 Late treatment -20% 1.20 [1.01-1.43] 42/1,098 33/1,017 20% higher risk All studies -15% 1.15 [0.92-1.44] 44/1,178 39/1,097 15% higher risk 6 convalescent plasma COVID-19 ICU results c19early.org Sep 2023 Tau​2​ = 0.02, I​2​ = 26.5%, p = 0.23 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ C3PO Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 Improvement, RR [CI] Treatment Control Alemany (DB RCT) -5% 1.05 [0.60-1.84] hosp. 22/188 21/188 Gharbharan (DB RCT) 39% 0.61 [0.28-1.34] hosp. 10/207 18/209 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.39 Early treatment 11% 0.89 [0.68-1.16] 83/652 95/651 11% lower risk Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Improvement, RR [CI] Treatment Control AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) Pouladza.. (SB RCT) -30% 1.30 [0.99-1.71] hosp. time 30 (n) 30 (n) PLACOVID Sekine (RCT) -67% 1.67 [0.01-470] hosp. time 80 (n) 80 (n) Holm (RCT) -62% 1.62 [0.76-3.46] hosp. time 17 (n) 14 (n) Sullivan (DB RCT) 54% 0.46 [0.26-0.80] hosp. 17/592 37/589 Jalili (RCT) -10% 1.10 [0.89-1.36] hosp. time 60 (n) 60 (n) CORIPLASM Lacombe (RCT) -7% 1.07 [0.00-9700] hosp. time 60 (n) 60 (n) Alshamrani (PSM) -32% 1.32 [1.07-1.63] hosp. time 41 (n) 205 (n) Tau​2​ = 0.06, I​2​ = 67.1%, p = 0.93 Late treatment 1% 0.99 [0.78-1.24] 17/914 37/1,073 1% lower risk All studies 4% 0.96 [0.80-1.16] 100/1,566 132/1,724 4% lower risk 12 convalescent plasma COVID-19 hospitalization results c19early.org Sep 2023 Tau​2​ = 0.05, I​2​ = 59.4%, p = 0.71 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 36% higher risk Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Improvement, RR [CI] Treatment Control Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Gonzalez -7% 1.07 [0.76-1.50] death 60/130 26/60 OT​1​ Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] death 3/30 5/30 Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] death 16/59 5/15 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] death 18/80 13/80 COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] death 10/69 8/67 CAPRI Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] death 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] death 11/53 17/52 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] death 14/231 19/240 Holm (RCT) 45% 0.55 [0.11-2.84] death 2/17 3/14 CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] death 40 (n) 39 (n) Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Jalili (RCT) -45% 1.45 [0.74-2.87] death 16/60 11/60 Baldeón (DB RCT) 12% 0.88 [0.37-2.11] death 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] death 11/52 13/51 De Santis (RCT) 13% 0.87 [0.48-1.56] death 11/36 25/71 Rojas (SB RCT) -220% 3.20 [0.64-16.0] death 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] death 22/87 7/42 CORIPLASM Lacombe (RCT) 49% 0.51 [0.20-1.32] death 7/60 12/60 CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] death 15/98 4/46 PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] death 89/482 80/465 REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] death 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] death 68 (n) 66 (n) Alshamrani (PSM) -14% 1.14 [0.79-1.45] death 24/41 108/205 Krishnan -270% 3.70 [0.90-15.8] death case control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.94 Late treatment -0% 1.00 [0.95-1.05] 2,408/11,225 2,330/10,446 0% higher risk All studies -0% 1.00 [0.96-1.05] 2,421/11,978 2,340/11,201 0% higher risk 41 convalescent plasma COVID-19 serious outcomes c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.91 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alemany (DB RCT) -5% 1.05 [0.85-1.30] no recov. 188 (n) 188 (n) Improvement, RR [CI] Treatment Control Gharbharan (DB RCT) -1% 1.01 [0.88-1.16] no recov. 137/207 137/209 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.73 Early treatment -2% 1.02 [0.91-1.15] 137/395 137/397 2% higher risk RECOVERY Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Improvement, RR [CI] Treatment Control Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) CAPSID Körper (RCT) 16% 0.84 [0.62-1.14] no recov. 30/53 35/52 PROTECT-Patient van den Berg (RCT) -3% 1.03 [0.62-1.71] no disch. 18/46 19/50 Rojas (SB RCT) 38% 0.62 [0.40-0.97] no disch. 46 (n) 45 (n) CSSC-004 Baksh (DB RCT) -1% 1.01 [0.94-1.09] no recov. 381/538 381/532 Tau​2​ = 0.00, I​2​ = 16.3%, p = 0.85 Late treatment 1% 0.99 [0.94-1.05] 2,392/6,521 2,376/6,485 1% lower risk All studies -0% 1.00 [0.97-1.04] 2,529/6,916 2,513/6,882 0% higher risk 8 convalescent plasma COVID-19 recovery results c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.85 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alemany (DB RCT) -4% 1.04 [0.97-1.11] viral load 188 (n) 188 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.33 Early treatment -4% 1.04 [0.97-1.11] 0/188 0/188 4% higher risk Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Improvement, RR [CI] Treatment Control PLACID Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) COVIDIT Kirenga (RCT) -50% 1.50 [0.81-2.77] viral time 67 (n) 67 (n) Rojas (SB RCT) -25% 1.25 [0.36-4.33] viral+ 46 (n) 45 (n) Tau​2​ = 0.15, I​2​ = 65.5%, p = 0.22 Late treatment 25% 0.75 [0.48-1.18] 60/326 91/319 25% lower risk All studies 17% 0.83 [0.60-1.15] 60/514 91/507 17% lower risk 6 convalescent plasma COVID-19 viral clearance results c19early.org Sep 2023 Tau​2​ = 0.09, I​2​ = 74.8%, p = 0.26 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 36% higher risk Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Improvement, RR [CI] Treatment Control Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] death 3/30 5/30 Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] death 16/59 5/15 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] death 18/80 13/80 COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] death 10/69 8/67 CAPRI Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] death 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] death 11/53 17/52 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] death 14/231 19/240 Holm (RCT) 45% 0.55 [0.11-2.84] death 2/17 3/14 CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] death 40 (n) 39 (n) Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Jalili (RCT) -45% 1.45 [0.74-2.87] death 16/60 11/60 Baldeón (DB RCT) 12% 0.88 [0.37-2.11] death 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] death 11/52 13/51 De Santis (RCT) 13% 0.87 [0.48-1.56] death 11/36 25/71 Rojas (SB RCT) -220% 3.20 [0.64-16.0] death 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] death 22/87 7/42 CORIPLASM Lacombe (RCT) 49% 0.51 [0.20-1.32] death 7/60 12/60 CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] death 15/98 4/46 PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] death 89/482 80/465 REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] death 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] death 68 (n) 66 (n) CSSC-004 Baksh (DB RCT) -1% 1.01 [0.94-1.09] no recov. 381/538 381/532 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Late treatment 0% 1.00 [0.96-1.04] 2,705/11,592 2,577/10,713 0% lower risk All studies -0% 1.00 [0.96-1.04] 2,718/12,345 2,587/11,468 0% higher risk 39 convalescent plasma COVID-19 Randomized Controlled Trials c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.99 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 36% higher risk Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Improvement, RR [CI] Treatment Control Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] 3/30 5/30 Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] 16/59 5/15 Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] 18/80 13/80 COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] 10/69 8/67 CAPRI Hsue (DB RCT) -212% 3.12 [0.14-71.7] 1/16 0/18 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] 11/53 17/52 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] 14/231 19/240 Holm (RCT) 45% 0.55 [0.11-2.84] 2/17 3/14 CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] 59/462 71/462 PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] 40 (n) 39 (n) Sullivan (DB RCT) 86% 0.14 [0.01-2.75] 0/592 3/589 Jalili (RCT) -45% 1.45 [0.74-2.87] 16/60 11/60 Baldeón (DB RCT) 12% 0.88 [0.37-2.11] 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] 11/52 13/51 De Santis (RCT) 13% 0.87 [0.48-1.56] 11/36 25/71 Rojas (SB RCT) -220% 3.20 [0.64-16.0] 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] 22/87 7/42 CORIPLASM Lacombe (RCT) 49% 0.51 [0.20-1.32] 7/60 12/60 CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] 15/98 4/46 PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] 89/482 80/465 REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] 68 (n) 66 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Late treatment 0% 1.00 [0.95-1.05] 2,324/11,054 2,196/10,181 0% lower risk All studies 0% 1.00 [0.95-1.05] 2,337/11,807 2,206/10,936 0% lower risk 38 convalescent plasma COVID-19 RCT mortality results c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.89 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 36% higher risk Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Improvement, RR [CI] Treatment Control Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] death 3/30 5/30 Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] death 16/59 5/15 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] death 18/80 13/80 COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] death 10/69 8/67 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] death 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] death 11/53 17/52 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] death 14/231 19/240 Holm (RCT) 45% 0.55 [0.11-2.84] death 2/17 3/14 CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] death 40 (n) 39 (n) Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Jalili (RCT) -45% 1.45 [0.74-2.87] death 16/60 11/60 Baldeón (DB RCT) 12% 0.88 [0.37-2.11] death 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] death 11/52 13/51 De Santis (RCT) 13% 0.87 [0.48-1.56] death 11/36 25/71 Rojas (SB RCT) -220% 3.20 [0.64-16.0] death 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] death 22/87 7/42 CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] death 15/98 4/46 PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] death 89/482 80/465 REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] death 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] death 68 (n) 66 (n) CSSC-004 Baksh (DB RCT) -1% 1.01 [0.94-1.09] no recov. 381/538 381/532 Alshamrani (PSM) -14% 1.14 [0.79-1.45] death 24/41 108/205 Krishnan -270% 3.70 [0.90-15.8] death case control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.88 Late treatment -0% 1.00 [0.96-1.05] 2,718/11,543 2,672/10,825 0% higher risk All studies -0% 1.00 [0.96-1.05] 2,731/12,296 2,682/11,580 0% higher risk 38 convalescent plasma COVID-19 peer reviewed studies c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] ventilation 2/80 4/80 INFANT-COVID-19 Libster (DB RCT) 67% 0.33 [0.07-1.60] ICU 2/80 6/80 INFANT-COVID-19 Libster (DB RCT) 48% 0.52 [0.29-0.94] progression 13/80 25/80 Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Balcells (RCT) -163% 2.63 [0.43-9.10] ventilation 5/28 2/30 Balcells (RCT) -23% 1.23 [0.56-1.89] progression 13/28 12/30 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 C3PO Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 C3PO Korley (RCT) 6% 0.94 [0.72-1.22] progression 77/257 81/254 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Alemany (DB RCT) -5% 1.05 [0.60-1.84] hosp. 22/188 21/188 Alemany (DB RCT) -5% 1.05 [0.85-1.30] no recov. 188 (n) 188 (n) Alemany (DB RCT) -4% 1.04 [0.97-1.11] viral load 188 (n) 188 (n) Alemany (DB RCT) 4% 0.96 [0.88-1.05] viral load 188 (n) 188 (n) Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Gharbharan (DB RCT) 67% 0.33 [0.01-8.16] ventilation 0/207 1/209 Gharbharan (DB RCT) 14% 0.86 [0.59-1.22] progression 207 (n) 209 (n) Gharbharan (DB RCT) 42% 0.58 [0.33-1.02] progression 123 (n) 103 (n) Gharbharan (DB RCT) 39% 0.61 [0.28-1.34] hosp. 10/207 18/209 Gharbharan (DB RCT) -50% 1.50 [0.40-5.64] hosp. time 207 (n) 209 (n) Gharbharan (DB RCT) -1% 1.01 [0.88-1.16] no recov. 137/207 137/209 Gharbharan (DB RCT) -8% 1.1 [0.00-9e+04] recov. time 207 (n) 209 (n) Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Li (RCT) 15% 0.85 [0.53-1.18] no improv. 25/52 29/51 Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Avendaño-Solà (RCT) 93% 0.07 [0.01-0.57] progression 0/38 7/43 Avendaño-Solà (RCT) 92% 0.08 [0.01-0.76] progression 0/38 6/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] progression 44/235 41/229 PLACID Agarwal (RCT) 1% 0.99 [0.54-1.81] ventilation 19/227 19/224 PLACID Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 Bajpai (RCT) -114% 2.14 [0.22-21.1] death 2/14 1/15 Bajpai (RCT) -221% 3.21 [0.38-27.4] ventilation 3/14 1/15 Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 AlQahtani (RCT) 33% 0.67 [0.22-2.01] ventilation 4/20 6/20 AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 PlasmAr Simonovich (RCT) 19% 0.81 [0.50-1.31] 7-point status 228 (n) 105 (n) Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 RECOVERY Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Gonzalez -7% 1.07 [0.76-1.50] death 60/130 26/60 OT​1​ Gonzalez -1% 1.01 [0.76-1.34] death 70/130 32/60 OT​1​ Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] death 3/30 5/30 Pouladza.. (SB RCT) -30% 1.30 [0.99-1.71] hosp. time 30 (n) 30 (n) Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] death 16/59 5/15 Bennett-.. (DB RCT) 11% 0.89 [0.34-2.31] death 14/59 4/15 Bennett-.. (DB RCT) 0% 1.00 [0.75-1.32] no improv. 47/59 12/15 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] death 18/80 13/80 PLACOVID Sekine (RCT) -100% 2.00 [0.72-5.59] death 10/80 5/80 PLACOVID Sekine (RCT) -11% 1.11 [0.74-1.66] no improv. 31/80 28/80 PLACOVID Sekine (RCT) -67% 1.67 [0.01-470] hosp. time 80 (n) 80 (n) COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] death 10/69 8/67 COVIDIT Kirenga (RCT) 9% 0.91 [0.38-2.16] progression 9/41 7/29 COVIDIT Kirenga (RCT) -50% 1.50 [0.81-2.77] viral time 67 (n) 67 (n) CAPRI Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 CAPRI Hsue (DB RCT) -12% 1.12 [0.08-16.6] death 1/16 1/18 CAPRI Hsue (DB RCT) -425% 5.25 [0.27-102] ventilation 2/16 0/18 CAPRI Hsue (DB RCT) -425% 5.25 [0.27-102] progression 2/16 0/18 CAPRI Hsue (DB RCT) -425% 5.25 [0.27-102] progression 2/16 0/18 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] death 320 (n) 163 (n) DAWn-plasma Devos (RCT) -8% 1.08 [0.65-1.80] ventilation 320 (n) 163 (n) DAWn-plasma Devos (RCT) 0% 1.00 [0.74-1.34] ICU 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 CONCOR-1 Bégin (RCT) -12% 1.12 [0.86-1.46] death 141/614 63/307 CONCOR-1 Bégin (RCT) -16% 1.16 [0.94-1.43] death/int. 199/614 86/307 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] death 11/53 17/52 CAPSID Körper (RCT) 14% 0.86 [0.34-2.20] death 7/53 8/52 CAPSID Körper (RCT) 16% 0.84 [0.62-1.14] no recov. 30/53 35/52 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] death 14/231 19/240 TSUNAMI Menichetti (RCT) -4% 1.04 [0.62-1.75] ventilation 25/231 25/240 TSUNAMI Menichetti (RCT) 12% 0.88 [0.59-1.33] progression 59/231 67/239 Holm (RCT) 45% 0.55 [0.11-2.84] death 2/17 3/14 Holm (RCT) 69% 0.31 [0.01-7.09] ventilation 0/17 1/14 Holm (RCT) 19% 0.81 [0.25-2.64] progression 4/16 4/13 Holm (RCT) -57% 1.57 [0.52-4.74] oxygen time 17 (n) 14 (n) Holm (RCT) -62% 1.62 [0.76-3.46] hosp. time 17 (n) 14 (n) CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 CONTAIN COVID-19 Ortigoza (DB RCT) 1% 0.99 [0.66-1.47] death 35/463 39/463 CONTAIN COVID-19 Ortigoza (DB RCT) 8% 0.92 [0.74-1.16] WHO scale 468 (n) 473 (n) CONTAIN COVID-19 Ortigoza (DB RCT) 6% 0.94 [0.75-1.18] WHO scale 468 (n) 473 (n) PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] death 40 (n) 39 (n) PennCCP2 Bar (RCT) 44% 0.56 [0.24-1.29] no improv. 40 (n) 39 (n) PennCCP2 Bar (RCT) 51% 0.49 [0.18-1.30] ventilation 5/40 10/39 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Sullivan (DB RCT) 25% 0.75 [0.17-3.32] ICU 3/592 4/589 Sullivan (DB RCT) 54% 0.46 [0.26-0.80] hosp. 17/592 37/589 Jalili (RCT) -45% 1.45 [0.74-2.87] death 16/60 11/60 Jalili (RCT) -8% 1.08 [0.72-1.63] ICU 27/60 25/60 Jalili (RCT) -250% 3.50 [0.76-16.2] ARDS 7/60 2/60 Jalili (RCT) -10% 1.10 [0.89-1.36] hosp. time 60 (n) 60 (n) Baldeón (DB RCT) 12% 0.88 [0.37-2.11] death 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] death 11/52 13/51 PROTECT-Patient van den Berg (RCT) 67% 0.33 [0.04-3.04] ventilation 1/52 3/51 PROTECT-Patient van den Berg (RCT) 5% 0.95 [0.55-1.63] no improv. 16/47 18/50 PROTECT-Patient van den Berg (RCT) -3% 1.03 [0.62-1.71] no disch. 18/46 19/50 De Santis (RCT) 13% 0.87 [0.48-1.56] death 11/36 25/71 De Santis (RCT) 12% 0.88 [0.42-1.82] death 8/36 18/71 Rojas (SB RCT) -220% 3.20 [0.64-16.0] death 46 (n) 45 (n) Rojas (SB RCT) 38% 0.62 [0.40-0.97] no disch. 46 (n) 45 (n) Rojas (SB RCT) -25% 1.25 [0.36-4.33] viral+ 46 (n) 45 (n) Rojas (SB RCT) -16% 1.16 [0.33-4.08] viral+ 46 (n) 45 (n) Rojas (SB RCT) -51% 1.51 [0.33-6.98] viral+ 46 (n) 45 (n) Rojas (SB RCT) -12% 1.12 [0.16-7.84] viral+ 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] death 22/87 7/42 CORIPLASM Lacombe (RCT) 49% 0.51 [0.20-1.32] death 7/60 12/60 CORIPLASM Lacombe (RCT) 64% 0.36 [0.14-0.97] death 4/22 11/27 CORIPLASM Lacombe (RCT) -68% 1.68 [0.74-3.35] progression 13/60 8/60 CORIPLASM Lacombe (RCT) -4% 1.04 [0.61-1.78] progression 19/60 20/60 CORIPLASM Lacombe (RCT) -7% 1.07 [0.00-9700] hosp. time 60 (n) 60 (n) CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] death 15/98 4/46 CCAP-2 Thorlaci.. (DB RCT) -88% 1.88 [0.56-6.33] death 12/98 3/46 CCAP-2 Thorlaci.. (DB RCT) -72% 1.72 [0.50-5.87] death 11/98 3/46 CCAP-2 Thorlaci.. (DB RCT) -64% 1.64 [0.36-7.60] death 7/98 2/46 CCAP-2 Thorlaci.. (DB RCT) -735% 8.35 [0.47-148] death 5/98 0/46 CCAP-2 Thorlaci.. (DB RCT) -37% 1.37 [0.29-6.52] ventilation 6/94 2/43 CCAP-2 Thorlaci.. (DB RCT) -31% 1.31 [0.45-3.82] ICU 12/89 4/39 CCAP-2 Thorlaci.. (DB RCT) -41% 1.41 [0.72-2.09] 7-point status 98 (n) 46 (n) PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] death 89/482 80/465 PassItOn Self (DB RCT) -26% 1.26 [0.81-1.90] death 63/482 48/465 PassItOn Self (DB RCT) -4% 1.04 [0.82-1.33] 7-point status 487 (n) 473 (n) REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] death 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] death 68 (n) 66 (n) Denkinger (RCT) -2% 1.02 [0.59-1.77] ventilation 19/68 18/66 Denkinger (RCT) 22% 0.78 [0.52-1.16] 7-point status 68 (n) 66 (n) CSSC-004